Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Cash & Equivalents: 2009-2025

Historic Cash & Equivalents for Aytu Biopharma (AYTU) over the last 17 years, with Jun 2025 value amounting to $31.0 million.

  • Aytu Biopharma's Cash & Equivalents rose 62.27% to $32.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $32.6 million, marking a year-over-year increase of 62.27%. This contributed to the annual value of $31.0 million for FY2025, which is 54.71% up from last year.
  • Aytu Biopharma's Cash & Equivalents amounted to $31.0 million in FY2025, which was up 54.71% from $20.0 million recorded in FY2024.
  • Over the past 5 years, Aytu Biopharma's Cash & Equivalents peaked at $49.9 million during FY2021, and registered a low of $19.4 million during FY2022.
  • For the 3-year period, Aytu Biopharma's Cash & Equivalents averaged around $24.6 million, with its median value being $23.0 million (2023).
  • Per our database at Business Quant, Aytu Biopharma's Cash & Equivalents crashed by 61.20% in 2022 and then soared by 54.71% in 2025.
  • Over the past 5 years, Aytu Biopharma's Cash & Equivalents (Yearly) stood at $49.9 million in 2021, then slumped by 61.20% to $19.4 million in 2022, then grew by 18.72% to $23.0 million in 2023, then fell by 12.96% to $20.0 million in 2024, then soared by 54.71% to $31.0 million in 2025.